Oral pulse therapy with vitamin D3 for control of secondary hyperparathyroidism
Hebrew University-Hadassah Medical School Pediatric Nephrology
(Impact Factor: 2.86).
11/1994; 8(6):724-726. DOI: 10.1007/BF00869102
Twelve dialysis patients received oral pulse therapy with 1--hydroxyvitamin D3 in a dose of 0.1 g/kg body weight twice weekly and daily calcium carbonate (1.5–3.5 g) for a period of 8–12 months. This treatment was very effective in suppressing secondary hyperparathyroidism without causing hypercalcaemia and/or hyperphosphataemia.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.